Abstract
Does the inclusion of children in pharmacogenomic research raise new ethical issues? Through an exploration of the relevant laws, policies, guidelines and literature, we have identified five areas of concern and assessed their potential impact. These include (1) the difficulty of assessing risk and the ethics of invasive sampling, (2) the consent and assent process, (3) the circumstances under which and to whom the results of trials should be returned, (4) the effect of pharmacogenomics on identifying and treating orphan groups, and (5) the effect of pharmacogenomics on the pediatric drug approval process and patient recruitment. We conclude that while including pharmacogenomics in research projects involving children does indeed raise ethical concerns, none of these are insurmountable, and in fact, pharmacogenomics provides a promising outlook for the development of research that will benefit children.
Keywords: Pharmacogenomics, children, ethics, law, policy
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenomics: Dont Forget the Children
Volume: 6 Issue: 2
Author(s): Y. Joly, G. Sillon, T. Silverstein, M. Krajinovic and D. Avard
Affiliation:
Keywords: Pharmacogenomics, children, ethics, law, policy
Abstract: Does the inclusion of children in pharmacogenomic research raise new ethical issues? Through an exploration of the relevant laws, policies, guidelines and literature, we have identified five areas of concern and assessed their potential impact. These include (1) the difficulty of assessing risk and the ethics of invasive sampling, (2) the consent and assent process, (3) the circumstances under which and to whom the results of trials should be returned, (4) the effect of pharmacogenomics on identifying and treating orphan groups, and (5) the effect of pharmacogenomics on the pediatric drug approval process and patient recruitment. We conclude that while including pharmacogenomics in research projects involving children does indeed raise ethical concerns, none of these are insurmountable, and in fact, pharmacogenomics provides a promising outlook for the development of research that will benefit children.
Export Options
About this article
Cite this article as:
Joly Y., Sillon G., Silverstein T., Krajinovic M. and Avard D., Pharmacogenomics: Dont Forget the Children, Current Pharmacogenomics and Personalized Medicine 2008; 6 (2) . https://dx.doi.org/10.2174/1875692110806020077
DOI https://dx.doi.org/10.2174/1875692110806020077 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Pyrazole Derivatives as Antitumor, Anti-Inflammatory and Antibacterial Agents
Mini-Reviews in Medicinal Chemistry The Comparison of Different Planes in Breast Ultrasonography
Current Medical Imaging Probiotics and Different Efficacy, How it can be Managed?
Current Drug Therapy Chalcones and Chromones in Copper-Catalyzed Azide–Alkyne Cycloadditions (CuAAC)
Current Organic Chemistry Patent Annotations
Recent Patents on DNA & Gene Sequences Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Upshot of PI3K Inhibitors as Anticancer Arsenal: A Short Review
Current Bioactive Compounds Substance P: Structure, Function, and Therapeutics
Current Topics in Medicinal Chemistry Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology 13-lncRNAs Signature to Improve Diagnostic and Prognostic Prediction of Hepatocellular Carcinoma
Combinatorial Chemistry & High Throughput Screening Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Pharmacogenomics of Human Multidrug Resistance Associated Proteins
Current Pharmacogenomics and Personalized Medicine NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry Exploiting Microglial Functions for the Treatment of Glioblastoma
Current Cancer Drug Targets Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers A Simplified Protocol Employing Elacridar in Rodents: A Screening Model in Drug Discovery to Assess P-gp Mediated Efflux at the Blood Brain Barrier
Drug Metabolism Letters